{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:46Z","timestamp":1788225406258,"version":"build-2803163510"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["T32CA247756"],"award-info":[{"award-number":["T32CA247756"]}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["CDMRP PCRP PC220539"],"award-info":[{"award-number":["CDMRP PCRP PC220539"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05369-3","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:08:20Z","timestamp":1781867300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet\u2013Prostate cancer crosstalk driving disparities and therapeutic vulnerabilities"],"prefix":"10.1007","volume":"17","author":[{"given":"Vera","family":"Mariani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"5369_CR1","first-page":"202","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, et al. Cancer statistics for African American\/Black People 2022. CA Cancer J Clin. 2022;72:202\u201329.","journal-title":"CA Cancer J Clin"},{"key":"5369_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"5369_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1210\/me.2013-1039","volume":"27","author":"IJ Powell","year":"2013","unstructured":"Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013;27:879\u201391.","journal-title":"Mol Endocrinol"},{"key":"5369_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1158\/1055-9965.EPI-12-1238","volume":"22","author":"IJ Powell","year":"2013","unstructured":"Powell IJ, Dyson G, Land S. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomark Prev. 2013;22:891\u20137.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"5369_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajpa.24290","volume":"175","author":"CJ Mulligan","year":"2021","unstructured":"Mulligan CJ. Systemic racism can get under our skin and into our genes. Am J Phys Anthr. 2021;175:399\u2013405.","journal-title":"Am J Phys Anthr"},{"key":"5369_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1023\/A:1022216119066","volume":"22","author":"S Reddy","year":"2003","unstructured":"Reddy S, Shapiro M, Morton R Jr, Brawley OW. Prostate cancer in black and white Americans. Cancer Metastasis Rev. 2003;22:83\u20136.","journal-title":"Cancer Metastasis Rev"},{"key":"5369_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.juro.2006.09.024","volume":"177","author":"IJ Powell","year":"2007","unstructured":"Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol. 2007;177:444\u20139.","journal-title":"J Urol"},{"key":"5369_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.51745","volume":"6","author":"MS Pichardo","year":"2023","unstructured":"Pichardo MS, et al. Association of neighborhood deprivation with prostate cancer and immune markers in African American and European American Men. JAMA Netw Open. 2023;6:e2251745.","journal-title":"JAMA Netw Open"},{"key":"5369_CR9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/1055-9965.EPI-21-1064","volume":"31","author":"M Hansen","year":"2022","unstructured":"Hansen M, Hamieh NM, Markt SC. Racial disparities in prostate cancer: evaluation of diet, lifestyle, family history, and screening patterns. Cancer Epidemiol Biomark Prev. 2022;31:982\u201390.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"5369_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/oxfordjournals.aje.a010221","volume":"151","author":"AS Robbins","year":"2000","unstructured":"Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol. 2000;151:409\u201316.","journal-title":"Am J Epidemiol"},{"key":"5369_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ijc.23500","volume":"435","author":"S Evans","year":"2008","unstructured":"Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo. Investigating Black-White differences in prostate cancer prognosis: a systematic review and meta-analysis. Int J Cancer. 2008;435:430\u20135.","journal-title":"Int J Cancer"},{"key":"5369_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jnci\/93.5.388","volume":"93","author":"RM Hoffman","year":"2001","unstructured":"Hoffman RM, Gilliland FD, Eley JW. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001;93:388\u201395.","journal-title":"J Natl Cancer Inst"},{"key":"5369_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jnci\/93.3.219","volume":"93","author":"I Thompson","year":"2001","unstructured":"Thompson I, et al. Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst. 2001;93:219\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"5369_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/pros.20052","volume":"62","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate. 2005;62:243\u201352.","journal-title":"Prostate"},{"key":"5369_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ajpa.24144","volume":"175","author":"K Batai","year":"2021","unstructured":"Batai K, Hooker S, Kittles RA. Leveraging genetic ancestry to study health disparities. Am J Phys Anthr. 2021;175:363\u201375.","journal-title":"Am J Phys Anthr"},{"key":"5369_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/cncr.33224","volume":"127","author":"RR McKay","year":"2021","unstructured":"McKay RR, Sarkar RR, Kumar A. Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. Cancer. 2021;127:403\u201311.","journal-title":"Cancer"},{"key":"5369_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","volume":"5","author":"RT Dess","year":"2019","unstructured":"Dess RT, Hartman HE, Mahal BA. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019;5:975\u201383.","journal-title":"JAMA Oncol"},{"key":"5369_CR18","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1001\/jama.2018.11716","volume":"320","author":"BA Mahal","year":"2018","unstructured":"Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer-specific mortality across gleason scores in black vs nonblack men. JAMA. 2018;320:2479\u201381.","journal-title":"JAMA"},{"key":"5369_CR19","doi-asserted-by":"crossref","unstructured":"Johnson, W.-B., JR, L, H., SE, B., Jr., K, K., & R.A. Genetic Contributions to Prostate Cancer Disparities in Men of West African Descent. Front Oncol 11, (2021).","DOI":"10.3389\/fonc.2021.770500"},{"key":"5369_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/jamaoncol.2019.0812","volume":"5","author":"CJ Paller","year":"2019","unstructured":"Paller CJ, Wang L, Brawley OW. Racial inequality in prostate cancer outcomes-socioeconomics. Not Biol JAMA Oncol. 2019;5:983\u20134.","journal-title":"Not Biol JAMA Oncol"},{"key":"5369_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.gde.2018.06.008","volume":"53","author":"CJ Mulligan","year":"2018","unstructured":"Mulligan CJ. Insights from epigenetic studies on human health and evolution. Curr Opin Genet Dev. 2018;53:36\u201342.","journal-title":"Curr Opin Genet Dev"},{"key":"5369_CR22","doi-asserted-by":"publisher","first-page":"e2341651","DOI":"10.1001\/jamanetworkopen.2023.41651","volume":"6","author":"Jenkins","year":"2023","unstructured":"Jenkins, et al. Neighborhood deprivation and DNA methylation and expression of cancer genes in breast tumors. JAMA Netw Open. 2023;6:e2341651.","journal-title":"JAMA Netw Open"},{"key":"5369_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/OP.21.00297","volume":"22","author":"KT Ashing","year":"2022","unstructured":"Ashing KT, Jones V, Bedell F, Phillips T, Erhunmwunsee. Calling attention to the role of race-driven societal determinants of health on aggressive tumor biology: a focus on Black Americans. JCO Oncology Practice. 2022;22:15\u201322.","journal-title":"JCO Oncology Practice"},{"key":"5369_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/carcin\/bgs326","volume":"120","author":"D Tang","year":"2013","unstructured":"Tang D, Kryvenko ON, Wang. Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. Carcinogenesis. 2013;120:113\u201320.","journal-title":"Carcinogenesis"},{"key":"5369_CR25","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMc2000069","volume":"1085","author":"BA Mahal","year":"2020","unstructured":"Mahal BA, Alshalalfa M, Kensler. Racial differences in genomic profiling of prostate cancer. N Engl J Med. 2020;1085:1083\u20135.","journal-title":"N Engl J Med"},{"key":"5369_CR26","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-19-4112","volume":"4660","author":"Y Koga","year":"2020","unstructured":"Koga Y, Song H, Chalmers. Genomic profiling of prostate cancers from men with African and European ancestry. Clin Cancer Res. 2020;4660:4651\u201360.","journal-title":"Clin Cancer Res"},{"key":"5369_CR27","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-09-3342","volume":"3547","author":"B Kwabi-Addo","year":"2010","unstructured":"Kwabi-Addo B, Wang S, Chung. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res. 2010;3547:3539\u201347.","journal-title":"Clin Cancer Res"},{"key":"5369_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/15592294.2015.1022019","volume":"328","author":"JM Devaney","year":"2015","unstructured":"Devaney JM, Wang S, Furbert-Harris. Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. Epigenetics. 2015;328:319\u201328.","journal-title":"Epigenetics"},{"key":"5369_CR29","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.21873\/anticanres.13790","volume":"39","author":"V Apprey","year":"2019","unstructured":"Apprey V, Wang S, Tang W. Association of genetic ancestry with DNA methylation changes in prostate cancer disparity. Anticancer Res. 2019;39:5861\u20136.","journal-title":"Anticancer Res"},{"key":"5369_CR30","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nrc3341","volume":"12","author":"BE Henderson","year":"2012","unstructured":"Henderson BE, Lee NH, Seewaldt V, Shen H. The influence of race and ethnicity on the biology of cancer. Nat Rev Cancer. 2012;12:648\u201353.","journal-title":"Nat Rev Cancer"},{"key":"5369_CR31","doi-asserted-by":"publisher","first-page":"763569","DOI":"10.1155\/2013\/763569","volume":"2013","author":"BD Wang","year":"2013","unstructured":"Wang BD, Yang Q, Ceniccola K. Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer. 2013;2013:763569.","journal-title":"Prostate Cancer"},{"key":"5369_CR32","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.surg.2021.03.031","volume":"170","author":"IN Haskins","year":"2021","unstructured":"Haskins IN, Wang BD, Bernot JP. Genomics of Black American colon cancer disparities: an RNA sequencing (RNA-Seq) study from an academic, tertiary referral center. Surgery. 2021;170:1160\u20137.","journal-title":"Surgery"},{"key":"5369_CR33","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1158\/1078-0432.CCR-14-1566","volume":"21","author":"BD Wang","year":"2015","unstructured":"Wang BD, Ceniccola K, Yang Q. Identification and functional validation of reciprocal microRNA-mRNA Pairings in African American prostate cancer disparities. Clin Cancer Res. 2015;21:4970\u201384.","journal-title":"Clin Cancer Res"},{"key":"5369_CR34","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/1541-7786.MCR-19-0415","volume":"17","author":"J Olender","year":"2019","unstructured":"Olender J, Wang BD, Ching T. A novel FGFR3 splice variant preferentially expressed in African American prostate cancer drives aggressive phenotypes and docetaxel resistance. Mol Cancer Res. 2019;17:2115\u201325.","journal-title":"Mol Cancer Res"},{"key":"5369_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15921","author":"BD Wang","year":"2017","unstructured":"Wang BD, Ceniccola K, Hwang. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nat Commun. 2017. https:\/\/doi.org\/10.1038\/ncomms15921.","journal-title":"Nat Commun"},{"key":"5369_CR36","doi-asserted-by":"crossref","unstructured":"Wang, B. D. & Lee, N. H. Aberrant RNA Splicing in Cancer and Drug Resistance. vol. 10 (2018).","DOI":"10.3390\/cancers10110458"},{"key":"5369_CR37","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/0008-5472.CAN-07-2608","volume":"68","author":"TA Wallace","year":"2008","unstructured":"Wallace TA, Prueitt RL, Yi M. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68:927\u201336.","journal-title":"Cancer Res"},{"key":"5369_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02140-y","author":"W Rayford","year":"2021","unstructured":"Rayford W, Beksac AT, Alger. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Commun Biol. 2021. https:\/\/doi.org\/10.1038\/s42003-021-02140-y.","journal-title":"Commun Biol"},{"key":"5369_CR39","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/1078-0432.CCR-20-2925","volume":"27","author":"S Awasthi","year":"2021","unstructured":"Awasthi S, Berglund A, Abraham-Miranda J. Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clin Cancer Res. 2021;27:320\u20139.","journal-title":"Clin Cancer Res"},{"key":"5369_CR40","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1242\/jcs.03053","volume":"119","author":"A Srebrow","year":"2006","unstructured":"Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci. 2006;119:2635\u201341.","journal-title":"J Cell Sci"},{"key":"5369_CR41","doi-asserted-by":"crossref","unstructured":"Germann, S., Gratadou, L., Dutertre, M. & Auboeuf, D. Splicing programs and cancer. J Nucleic Acids 2012, (2012).","DOI":"10.1155\/2012\/269570"},{"key":"5369_CR42","doi-asserted-by":"crossref","unstructured":"Zhang, D., Hu, Q. & Liu, X. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nat Commun 11, (2020).","DOI":"10.1038\/s41467-020-15815-7"},{"key":"5369_CR43","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/nrurol.2009.125","volume":"6","author":"P Rajan","year":"2009","unstructured":"Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol. 2009;6:454\u201360.","journal-title":"Nat Rev Urol"},{"key":"5369_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4161\/rna.7.4.12152","volume":"7","author":"M Dutertre","year":"2010","unstructured":"Dutertre M, Vagner S, Auboeuf D. Alternative splicing and breast cancer. RNA Biol. 2010;7:403\u201311.","journal-title":"RNA Biol"},{"key":"5369_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1155\/2010\/705847","volume":"28","author":"GS Omenn","year":"2010","unstructured":"Omenn GS, Yocum AK, Menon R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Markers. 2010;28:241\u201351.","journal-title":"Markers"},{"key":"5369_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature08909","volume":"463","author":"TW Nilsen","year":"2010","unstructured":"Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463:457\u201363.","journal-title":"Nature"},{"key":"5369_CR47","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/ng.259","volume":"40","author":"Q Pan","year":"2008","unstructured":"Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413\u20135.","journal-title":"Nat Genet"},{"key":"5369_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/463786","volume":"2013","author":"M Ladomery","year":"2013","unstructured":"Ladomery M. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013;2013:1\u20136.","journal-title":"Int J Cell Biol"},{"key":"5369_CR49","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"5369_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-030-22254-3_10","volume":"1164","author":"J Olender","year":"2019","unstructured":"Olender J, Lee NH. Role of alternative splicing in prostate cancer aggressiveness and drug resistance in African Americans. Adv Exp Med Biol. 2019;1164:119\u201339.","journal-title":"Adv Exp Med Biol"},{"key":"5369_CR51","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ajpath.2017.06.019","volume":"188","author":"CJ Smith","year":"2018","unstructured":"Smith CJ, Minas TZ, Ambs S. Analysis of tumor biology to advance cancer health disparity research. Am J Pathol. 2018;188:304\u201316.","journal-title":"Am J Pathol"},{"key":"5369_CR52","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.18632\/oncotarget.28024","volume":"12","author":"F Rahmatpanah","year":"2021","unstructured":"Rahmatpanah F, Robles G, Lilly M. RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans. Oncotarget. 2021;12:1457\u201369.","journal-title":"Oncotarget"},{"key":"5369_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ijc.28326","volume":"134","author":"MA Kinseth","year":"2014","unstructured":"Kinseth MA, Jia Z, Rahmatpanah F. Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer. 2014;134:81\u201391.","journal-title":"Int J Cancer"},{"key":"5369_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrc2090","volume":"7","author":"AM De Marzo","year":"2007","unstructured":"De Marzo AM, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256\u201369.","journal-title":"Nat Rev Cancer"},{"key":"5369_CR55","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1027","volume":"26","author":"CJ Smith","year":"2017","unstructured":"Smith CJ, et al. Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American Men. Cancer Epidemiol Biomark Prev. 2017;26:845\u201353.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"5369_CR56","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1038\/s41598-023-29450-x","volume":"13","author":"K Garofano","year":"2023","unstructured":"Garofano K, et al. Prostate cancer cell-platelet bidirectional signaling promotes calcium mobilization, invasion and apoptotic resistance via distinct receptor-ligand pairs. Sci Rep. 2023;13:2864.","journal-title":"Sci Rep"},{"key":"5369_CR57","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","volume":"640","author":"J Yang","year":"2025","unstructured":"Yang J, et al. Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature. 2025;640:1052\u201361.","journal-title":"Nature"},{"key":"5369_CR58","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/cancers14092192","volume":"14","author":"O Le Chapelain","year":"2022","unstructured":"Le Chapelain O, Ho-Tin-No\u00e9 B. Intratumoral platelets: harmful or incidental bystanders of the tumor microenvironment? Cancers. 2022;14:2192.","journal-title":"Cancers"},{"key":"5369_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111298","volume":"40","author":"T Pereira-Veiga","year":"2022","unstructured":"Pereira-Veiga T, Schneegans S, Pantel K, Wikman H. Circulating tumor cell-blood cell crosstalk: biology and clinical relevance. Cell Rep. 2022;40:111298.","journal-title":"Cell Rep"},{"key":"5369_CR60","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","volume":"10","author":"AL Palacios-Acedo","year":"2019","unstructured":"Palacios-Acedo AL, et al. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805.","journal-title":"Front Immunol"},{"key":"5369_CR61","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-022-00272-3","volume":"11","author":"V Giannakeas","year":"2022","unstructured":"Giannakeas V. Trends in platelet count among cancer patients. Exp Hematol Oncol. 2022;11:16.","journal-title":"Exp Hematol Oncol"},{"key":"5369_CR62","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/cancers14030549","volume":"14","author":"V Giannakeas","year":"2022","unstructured":"Giannakeas V, et al. Platelet count and survival after cancer. Cancers. 2022;14:549.","journal-title":"Cancers"},{"key":"5369_CR63","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3346\/jkms.2014.29.4.507","volume":"29","author":"KH Kim","year":"2014","unstructured":"Kim KH, et al. Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci. 2014;29:507\u201311.","journal-title":"J Korean Med Sci"},{"key":"5369_CR64","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJM200006293422604","volume":"1958","author":"S Schulman","year":"2000","unstructured":"Schulman S, Lindmarker. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med. 2000;1958:1953\u20138.","journal-title":"N Engl J Med"},{"key":"5369_CR65","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","volume":"366","author":"RL Stone","year":"2012","unstructured":"Stone RL, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610\u20138.","journal-title":"N Engl J Med"},{"key":"5369_CR66","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/cncr.22237","volume":"107","author":"R Suppiah","year":"2006","unstructured":"Suppiah R, Shaheen PE, Elson P. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006;107:1793\u2013800.","journal-title":"Cancer"},{"key":"5369_CR67","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ijsu.2018.11.020","volume":"60","author":"J Guo","year":"2018","unstructured":"Guo J, et al. Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: a meta-analysis of results from multivariate analysis. Int J Surg. 2018;60:216\u201323.","journal-title":"Int J Surg"},{"key":"5369_CR68","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.3390\/cancers13184690","volume":"13","author":"B Hayes","year":"2021","unstructured":"Hayes B, et al. Circulating tumour cell numbers correlate with platelet count and circulating lymphocyte subsets in men with advanced prostate cancer: data from the ExPeCT Clinical Trial (CTRIAL-IE 15\u201321). Cancers. 2021;13:4690.","journal-title":"Cancers"},{"key":"5369_CR69","first-page":"1713","volume":"143","author":"C Philippe","year":"1993","unstructured":"Philippe C, et al. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol. 1993;143:1713\u201323.","journal-title":"Am J Pathol"},{"key":"5369_CR70","first-page":"1295","volume":"59","author":"B Nieswandt","year":"1999","unstructured":"Nieswandt B, Hafner M, Echtenacher B, M\u00e4nnel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295\u2013300.","journal-title":"Cancer Res"},{"key":"5369_CR71","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1073\/pnas.061615598","volume":"98","author":"L Borsig","year":"2001","unstructured":"Borsig L, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci. 2001;98:3352\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"5369_CR72","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10585-014-9660-7","volume":"31","author":"K Egan","year":"2014","unstructured":"Egan K, Cooke N, Kenny D. Living in shear: platelets protect cancer cells from shear induced damage. Clin Exp Metastasis. 2014;31:697\u2013704.","journal-title":"Clin Exp Metastasis"},{"key":"5369_CR73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-020-0189-0","volume":"9","author":"E Marcolino","year":"2020","unstructured":"Marcolino E, et al. Blood platelets stimulate cancer extravasation through TGF\u03b2-mediated downregulation of PRH\/HHEX. Oncogenesis. 2020;9:10.","journal-title":"Oncogenesis"},{"key":"5369_CR74","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1158\/0008-5472.CAN-18-0887","volume":"78","author":"MG Best","year":"2018","unstructured":"Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring. Cancer Res. 2018;78:3407\u201312.","journal-title":"Cancer Res"},{"key":"5369_CR75","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1038\/onc.2012.447","volume":"32","author":"BA Kerr","year":"2013","unstructured":"Kerr BA, McCabe NP, Feng W, Byzova TV. Platelets govern pre-metastatic tumor communication to bone. Oncogene. 2013;32:4319\u201324.","journal-title":"Oncogene"},{"key":"5369_CR76","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/CIRCRESAHA.122.321861","volume":"132","author":"T Dudiki","year":"2023","unstructured":"Dudiki T, et al. Mechanism of tumor-platelet communications in cancer. Circ Res. 2023;132:1447\u201361.","journal-title":"Circ Res"},{"key":"5369_CR77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pros.23443","volume":"78","author":"L-A Tjon-Kon-Fat","year":"2018","unstructured":"Tjon-Kon-Fat L-A, et al. Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. Prostate. 2018;78:48\u201353.","journal-title":"Prostate"},{"key":"5369_CR78","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","volume":"33","author":"M Haemmerle","year":"2018","unstructured":"Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell. 2018;33:965\u201383.","journal-title":"Cancer Cell"},{"key":"5369_CR79","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1586\/14737140.4.2.303","volume":"4","author":"S Gao","year":"2004","unstructured":"Gao S, Escalante C. Venous thromboembolism and malignancy. Expert Rev Anticancer Ther. 2004;4:303\u201320.","journal-title":"Expert Rev Anticancer Ther"},{"key":"5369_CR80","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7326\/0003-4819-149-5-200809020-00007","volume":"149","author":"M Carrier","year":"2008","unstructured":"Carrier M, et al. Systematic review: the trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149:323\u201333.","journal-title":"Ann Intern Med"},{"key":"5369_CR81","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/2159-8290.CD-12-0329","volume":"1099","author":"M Labelle","year":"2012","unstructured":"Labelle M, Hynes. The initial hours of metastasis: the importance of cooperative host\u2013tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012;1099:1091\u20139.","journal-title":"Cancer Discov"},{"key":"5369_CR82","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood-2007-09-113837","volume":"111","author":"JE Italiano Jr","year":"2008","unstructured":"Italiano JE Jr, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet \u03b1 granules and differentially released. Blood. 2008;111:1227\u201333.","journal-title":"Blood"},{"key":"5369_CR83","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1182\/blood.V98.10.3143","volume":"98","author":"A Janowska-Wieczorek","year":"2001","unstructured":"Janowska-Wieczorek A, et al. Platelet-derived microparticles bind to hematopoietic stem\/progenitor cells and enhance their engraftment. Blood. 2001;98:3143\u20139.","journal-title":"Blood"},{"key":"5369_CR84","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1158\/1078-0432.CCR-14-0870","volume":"21","author":"J Bottsford-Miller","year":"2015","unstructured":"Bottsford-Miller J, et al. Differential platelet levels affect response to taxane-based therapy in ovarian cancer. Clin Cancer Res. 2015;21:602\u201310.","journal-title":"Clin Cancer Res"},{"key":"5369_CR85","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/0008-5472.CAN-10-2038","volume":"71","author":"M Demers","year":"2011","unstructured":"Demers M, Ho-Tin-No\u00e9 B, Schatzberg D, Yang JJ, Wagner DD. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011;71:1540\u20139.","journal-title":"Cancer Res"},{"key":"5369_CR86","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3892\/mmr.2012.760","volume":"5","author":"L Gong","year":"2012","unstructured":"Gong L, Mi HJ, Zhu H, Zhou X, Yang H. P-selectin-mediated platelet activation promotes adhesion of non-small cell lung carcinoma cells on vascular endothelial cells under flow. Mol Med Rep. 2012;5:935\u201342.","journal-title":"Mol Med Rep"},{"key":"5369_CR87","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1038\/s41598-017-04324-1","volume":"7","author":"K Miyata","year":"2017","unstructured":"Miyata K, Takemoto A, Okumura S, Nishio M, Fujita N. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Sci Rep. 2017;7:4059.","journal-title":"Sci Rep"},{"key":"5369_CR88","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/jth.13987","volume":"16","author":"T Sasaki","year":"2018","unstructured":"Sasaki T, Shirai T, Tsukiji N. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2\/podoplanin-dependent platelet aggregation and lung metastasis. J Thromb Haemost. 2018;16:960\u201372.","journal-title":"J Thromb Haemost"},{"key":"5369_CR89","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/jth.13604","volume":"15","author":"T Shirai","year":"2017","unstructured":"Shirai T, et al. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Haemost. 2017;15:513\u201325.","journal-title":"J Thromb Haemost"},{"key":"5369_CR90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jfda.2019.08.002","volume":"28","author":"C-P Tseng","year":"2020","unstructured":"Tseng C-P, et al. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2. J Food Drug Anal. 2020;28:115\u201323.","journal-title":"J Food Drug Anal"},{"key":"5369_CR91","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cellsig.2018.04.008","volume":"48","author":"M Zara","year":"2018","unstructured":"Zara M, et al. Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. Cell Signal. 2018;48:45\u201353.","journal-title":"Cell Signal"},{"key":"5369_CR92","doi-asserted-by":"publisher","first-page":"9325","DOI":"10.1073\/pnas.95.16.9325","volume":"95","author":"YJ Kim","year":"1998","unstructured":"Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci. 1998;95:9325\u201330.","journal-title":"Proc Natl Acad Sci"},{"key":"5369_CR93","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/ijc.24016","volume":"124","author":"O Dashevsky","year":"2009","unstructured":"Dashevsky O, Varon D, Brill A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer. 2009;124:1773\u20137.","journal-title":"Int J Cancer"},{"key":"5369_CR94","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/bjc.2017.214","volume":"117","author":"L Jiang","year":"2017","unstructured":"Jiang L, et al. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF\u2013integrin cooperative signalling. Br J Cancer. 2017;117:695\u2013703.","journal-title":"Br J Cancer"},{"key":"5369_CR95","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/jnci\/95.6.458","volume":"95","author":"H Uehara","year":"2003","unstructured":"Uehara H, Kim SJ, Karashima T. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003;95:458\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"5369_CR96","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"5369_CR97","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/j.1538-7836.2011.04443.x","volume":"9","author":"NA Zakai","year":"2011","unstructured":"Zakai NA, McCLURE LA. Racial differences in venous thromboembolism. J Thromb Haemost. 2011;9:1877\u201382.","journal-title":"J Thromb Haemost"},{"key":"5369_CR98","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","volume":"136","author":"MR Carnethon","year":"2017","unstructured":"Carnethon MR, et al. Cardiovascular health in african americans: a scientific statement from the American heart association. Circulation. 2017;136:e393\u2013423.","journal-title":"Circulation"},{"key":"5369_CR99","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/cncr.30687","volume":"123","author":"A Tsodikov","year":"2017","unstructured":"Tsodikov A, et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017;123:2312\u20139.","journal-title":"Cancer"},{"key":"5369_CR100","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632\u20134.","journal-title":"J Thromb Haemost"},{"key":"5369_CR101","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/COC.0000000000000639","volume":"43","author":"NO Addo-Tabiri","year":"2020","unstructured":"Addo-Tabiri NO, et al. Black patients experience highest rates of cancer-associated venous thromboembolism. Am J Clin Oncol. 2020;43:94\u2013100.","journal-title":"Am J Clin Oncol"},{"key":"5369_CR102","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/bloodadvances.2021006209","volume":"6","author":"T Datta","year":"2022","unstructured":"Datta T, Brunson A, Mahajan A, Keegan T, Wun T. Racial disparities in cancer-associated thrombosis. Blood Adv. 2022;6:3167\u201377.","journal-title":"Blood Adv"},{"key":"5369_CR103","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/00004872-199402000-00013","volume":"12","author":"M Kimura","year":"1994","unstructured":"Kimura M, Cho JH, Lasker N, Aviv A. Differences in platelet calcium regulation between African Americans and Caucasians: implications for the predisposition of African Americans to essential hypertension. J Hypertens. 1994;12:199\u2013207.","journal-title":"J Hypertens"},{"key":"5369_CR104","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/j.1538-7836.2007.02618.x","volume":"5","author":"PF Bray","year":"2007","unstructured":"Bray PF, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost JTH. 2007;5:1617\u201323.","journal-title":"J Thromb Haemost JTH"},{"key":"5369_CR105","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12863-015-0217-9","volume":"16","author":"R Qayyum","year":"2015","unstructured":"Qayyum R, et al. Genome-wide association study of platelet aggregation in African Americans. BMC Genet. 2015;16:58.","journal-title":"BMC Genet"},{"key":"5369_CR106","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cpt.2363","volume":"110","author":"K Garofano","year":"2021","unstructured":"Garofano K, et al. Differences in the platelet mRNA landscape portend racial disparities in platelet function and suggest novel therapeutic targets. Clin Pharmacol Ther. 2021;110:702\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"5369_CR107","doi-asserted-by":"publisher","first-page":"19421","DOI":"10.1074\/jbc.M308864200","volume":"279","author":"DE Roberts","year":"2004","unstructured":"Roberts DE, McNicol A, Bose R. Mechanism of collagen activation in human platelets. J Biol Chem. 2004;279:19421\u201330.","journal-title":"J Biol Chem"},{"key":"5369_CR108","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1349-7006.1990.tb02668.x","volume":"81","author":"J Ren","year":"1990","unstructured":"Ren J, et al. Correlation between the presence of microvilli and the growth or metastatic potential of tumor cells. Jpn J Cancer Res Gann. 1990;81:920\u20136.","journal-title":"Jpn J Cancer Res Gann"},{"key":"5369_CR109","doi-asserted-by":"publisher","first-page":"117822342110561","DOI":"10.1177\/11782234211056134","volume":"15","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, Krishnamurthy S, El-Zein R. Ultrastructural analysis of inflammatory breast cancer cell clusters in an Ex Vivo environment mechanically mimicking the lymph vascular system. Breast Cancer Basic Clin Res. 2021;15:11782234211056134.","journal-title":"Breast Cancer Basic Clin Res"},{"key":"5369_CR110","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1128\/MCB.00955-07","volume":"27","author":"J Yin","year":"2007","unstructured":"Yin J, et al. Activation of the RalGEF\/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007;27:7538\u201350.","journal-title":"Mol Cell Biol"},{"key":"5369_CR111","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.celrep.2018.03.092","volume":"23","author":"Y Ward","year":"2018","unstructured":"Ward Y, Lake R, Faraji F. Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinates transendothelial migration. Cell Rep. 2018;23:808\u201322.","journal-title":"Cell Rep"},{"key":"5369_CR112","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1038\/nm.3385","volume":"19","author":"LC Edelstein","year":"2013","unstructured":"Edelstein LC, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. 2013;19:1609\u201316.","journal-title":"Nat Med"},{"key":"5369_CR113","doi-asserted-by":"publisher","first-page":"2449344","DOI":"10.1080\/09537104.2024.2449344","volume":"36","author":"K Garofano","year":"2025","unstructured":"Garofano K, et al. Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects. Platelets. 2025;36:2449344.","journal-title":"Platelets"},{"key":"5369_CR114","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","volume":"77","author":"KC Day","year":"2017","unstructured":"Day KC, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017;77:74\u201385.","journal-title":"Cancer Res"},{"key":"5369_CR115","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-09-2546","volume":"1560","author":"Minner","year":"2010","unstructured":"Minner, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res. 2010;1560:1553\u201360.","journal-title":"Clin Cancer Res"},{"key":"5369_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2023.152219","volume":"67","author":"F Estephan","year":"2023","unstructured":"Estephan F, et al. The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma. Ann Diagn Pathol. 2023;67:152219.","journal-title":"Ann Diagn Pathol"},{"key":"5369_CR117","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1200\/JCO.2004.06.134","volume":"22","author":"B Shuch","year":"2004","unstructured":"Shuch B, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22:4725\u20139.","journal-title":"J Clin Oncol"},{"key":"5369_CR118","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/s41416-020-01052-8","volume":"123","author":"P Nasta\u0142y","year":"2020","unstructured":"Nasta\u0142y P, et al. EGFR as a stable marker of prostate cancer dissemination to bones. Br J Cancer. 2020;123:1767\u201374.","journal-title":"Br J Cancer"},{"key":"5369_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101642","volume":"31","author":"K Yumoto","year":"2023","unstructured":"Yumoto K, et al. HER2 as a potential therapeutic target on quiescent prostate cancer cells. Transl Oncol. 2023;31:101642.","journal-title":"Transl Oncol"},{"key":"5369_CR120","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/genes15070903","volume":"15","author":"X Cheng","year":"2024","unstructured":"Cheng X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes. 2024;15:903.","journal-title":"Genes"},{"key":"5369_CR121","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.1158\/1078-0432.CCR-12-2219","volume":"18","author":"R Cathomas","year":"2012","unstructured":"Cathomas R, et al. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08\/07). Clin Cancer Res. 2012;18:6049\u201357.","journal-title":"Clin Cancer Res"},{"key":"5369_CR122","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1200\/JCO.2006.08.8187","volume":"25","author":"DB Solit","year":"2007","unstructured":"Solit DB, Rosen N. Targeting HER2 in prostate cancer: where to next? J Clin Oncol. 2007;25:241\u20133.","journal-title":"J Clin Oncol"},{"key":"5369_CR123","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/COC.0b013e3181beac33","volume":"33","author":"SS Sridhar","year":"2010","unstructured":"Sridhar SS, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol. 2010;33:609\u201313.","journal-title":"Am J Clin Oncol"},{"key":"5369_CR124","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/cncr.20228","volume":"100","author":"PN Lara","year":"2004","unstructured":"Lara PN, et al. Trastuzumab plus docetaxel in HER-2\/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004;100:2125\u201331.","journal-title":"Cancer"},{"key":"5369_CR125","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/pros.20065","volume":"60","author":"A Ziada","year":"2004","unstructured":"Ziada A, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004;60:332\u20137.","journal-title":"Prostate"},{"key":"5369_CR126","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.2006.07.0888","volume":"25","author":"JS De Bono","year":"2007","unstructured":"De Bono JS, et al. Open-Label Phase II study evaluating the efficacy and safety of two doses of Pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007;25:257\u201362.","journal-title":"J Clin Oncol"},{"key":"5369_CR127","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc2875","volume":"10","author":"NJ Pyne","year":"2010","unstructured":"Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489\u2013503.","journal-title":"Nat Rev Cancer"},{"key":"5369_CR128","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.3390\/cancers15102732","volume":"15","author":"S Mebarek","year":"2023","unstructured":"Mebarek S, Skafi N, Brizuela L. Targeting sphingosine 1-phosphate metabolism as a therapeutic avenue for prostate cancer. Cancers. 2023;15:2732.","journal-title":"Cancers"},{"key":"5369_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216213","volume":"14","author":"JNJ Buie","year":"2019","unstructured":"Buie JNJ, et al. Differences in plasma levels of long chain and very long chain ceramides between African Americans and whites: An observational study. PLoS ONE. 2019;14:e0216213.","journal-title":"PLoS ONE"},{"key":"5369_CR130","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1476-511X-12-20","volume":"12","author":"Y Ono","year":"2013","unstructured":"Ono Y, et al. Sphingosine 1-phosphate release from platelets during clot formation: close correlation between platelet count and serum sphingosine 1-phosphate concentration. Lipids Health Dis. 2013;12:20.","journal-title":"Lipids Health Dis"},{"key":"5369_CR131","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-07-2322","volume":"1845","author":"Pchejetski","year":"2008","unstructured":"Pchejetski, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008;1845:1836\u201345.","journal-title":"Mol Cancer Ther"},{"key":"5369_CR132","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1158\/0008-5472.CAN-05-2702","volume":"11675","author":"Pchejetski","year":"2005","unstructured":"Pchejetski, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005;11675:11667\u201375.","journal-title":"Cancer Res"},{"key":"5369_CR133","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1002\/ijc.24640","volume":"2736","author":"Sauer","year":"2009","unstructured":"Sauer, et al. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer. 2009;2736:2728\u201336.","journal-title":"Int J Cancer"},{"key":"5369_CR134","doi-asserted-by":"publisher","first-page":"eaah4007","DOI":"10.1126\/scisignal.aah4007","volume":"10","author":"G Andrieu","year":"2017","unstructured":"Andrieu G, et al. Sphingosine 1-phosphate signaling through its receptor S1P5 promotes chromosome segregation and mitotic progression. Sci Signal. 2017;10:eaah4007.","journal-title":"Sci. Signal."},{"key":"5369_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.807639","volume":"13","author":"S Pournajaf","year":"2022","unstructured":"Pournajaf S, Dargahi L, Javan M, Pourgholami MH. Molecular pharmacology and novel potential therapeutic applications of fingolimod. Front Pharmacol. 2022;13:807639.","journal-title":"Front Pharmacol"},{"key":"5369_CR136","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/(SICI)1097-0045(19990615)40:1<50::AID-PROS6>3.0.CO;2-N","volume":"40","author":"JD Wang","year":"1999","unstructured":"Wang JD, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate. 1999;40:50\u20135.","journal-title":"Prostate"},{"key":"5369_CR137","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2005.02.039","volume":"233","author":"C Zhou","year":"2006","unstructured":"Zhou C, et al. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. 2006;233:36\u201347.","journal-title":"Cancer Lett"},{"key":"5369_CR138","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1158\/0008-5472.CAN-10-1388","volume":"70","author":"D Pchejetski","year":"2010","unstructured":"Pchejetski D, et al. FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010;70:8651\u201361.","journal-title":"Cancer Res"},{"key":"5369_CR139","doi-asserted-by":"publisher","first-page":"21197","DOI":"10.1074\/jbc.M201289200","volume":"277","author":"T Sano","year":"2002","unstructured":"Sano T, et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem. 2002;277:21197\u2013206.","journal-title":"J Biol Chem"},{"key":"5369_CR140","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/ten.teb.2015.0107","volume":"21","author":"BYK Binder","year":"2015","unstructured":"Binder BYK, Williams PA, Silva EA, Leach JK. Lysophosphatidic acid and sphingosine-1-phosphate: a concise review of biological function and applications for tissue engineering. Tissue Eng Part B Rev. 2015;21:531\u201342.","journal-title":"Tissue Eng Part B Rev"},{"key":"5369_CR141","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1111\/bph.14362","volume":"175","author":"R Leblanc","year":"2018","unstructured":"Leblanc R, Houssin A, Peyruchaud O. Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis. Br J Pharmacol. 2018;175:3100\u201310.","journal-title":"Br J Pharmacol"},{"key":"5369_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/cells10082059","volume":"2059","author":"P Balijepalli","year":"2021","unstructured":"Balijepalli P, Sitton CC, Meier. Lysophosphatidic acid signaling in cancer cells: what makes LPA so special? Cells. 2021;2059:2059.","journal-title":"Cells"},{"key":"5369_CR143","unstructured":"Lin, Y.-C., Huang, Y.-L. & Lee, H. Lysophosphatidic acid in prostate cancer progression. Transl. Cancer Res. 4, (2015)."},{"key":"5369_CR144","first-page":"1305","volume":"1863","author":"Y-C Lin","year":"2018","unstructured":"Lin Y-C, et al. LPA1\/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer. Biochim Biophys Acta BBA Mol Cell Biol Lipids. 2018;1863:1305\u201315.","journal-title":"Biochim Biophys Acta BBA Mol Cell Biol Lipids"},{"key":"5369_CR145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097771","volume":"9","author":"David","year":"2014","unstructured":"David, et al. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. PLoS ONE. 2014;9:e97771.","journal-title":"PLoS ONE"},{"key":"5369_CR146","first-page":"3479","volume":"97","author":"M Suthanthiran","year":"2000","unstructured":"Suthanthiran M, et al. Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and\/or target organ damage. Proc Natl Acad Sci U S A. 2000;97:3479\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5369_CR147","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"590","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;590:576\u201390.","journal-title":"Cancer Cell"},{"key":"5369_CR148","doi-asserted-by":"publisher","first-page":"42186","DOI":"10.1038\/srep42186","volume":"7","author":"A Takemoto","year":"2017","unstructured":"Takemoto A, et al. A critical role of platelet TGF-\u03b2 release in podoplanin-mediated tumour invasion and metastasis. Sci Rep. 2017;7:42186.","journal-title":"Sci Rep"},{"key":"5369_CR149","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.thromres.2021.01.008","volume":"200","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Blocking podoplanin inhibits platelet activation and decreases cancer-associated venous thrombosis. Thromb Res. 2021;200:72\u201380.","journal-title":"Thromb Res"},{"key":"5369_CR150","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1186\/s12885-019-5808-9","volume":"19","author":"M Xu","year":"2019","unstructured":"Xu M, et al. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma. BMC Cancer. 2019;19:599.","journal-title":"BMC Cancer"},{"key":"5369_CR151","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/bloodadvances.2018016261","volume":"2","author":"N Tsukiji","year":"2018","unstructured":"Tsukiji N, et al. Cobalt hematoporphyrin inhibits CLEC-2\u2013podoplanin interaction, tumor metastasis, and arterial\/venous thrombosis in mice. Blood Adv. 2018;2:2214\u201325.","journal-title":"Blood Adv"},{"key":"5369_CR152","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1158\/1078-0432.CCR-21-4509","volume":"28","author":"A Takemoto","year":"2022","unstructured":"Takemoto A, et al. Targeting podoplanin for the treatment of osteosarcoma. Clin Cancer Res. 2022;28:2633\u201345.","journal-title":"Clin Cancer Res"},{"key":"5369_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114697","volume":"114697","author":"G de Streel","year":"2021","unstructured":"de Streel G, Lucas S. Targeting immunosuppression by TGF-\u03b21 for cancer immunotherapy. Biochem Pharmacol. 2021;114697:114697.","journal-title":"Biochem Pharmacol"},{"key":"5369_CR154","doi-asserted-by":"publisher","first-page":"7911","DOI":"10.1126\/sciimmunol.aai7911","volume":"2","author":"S Rachidi","year":"2017","unstructured":"Rachidi S, et al. Platelets subvert T cell immunity against cancer via GARP-TGF\u03b2 Axis. Sci Immunol. 2017;2:7911.","journal-title":"Sci. Immunol."},{"key":"5369_CR155","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","volume":"69","author":"H-G Kopp","year":"2009","unstructured":"Kopp H-G, Placke T, Salih HR. Platelet-derived transforming growth factor-\u03b2 down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69:7775\u201383.","journal-title":"Cancer Res"},{"key":"5369_CR156","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/pros.23708","volume":"79","author":"C Paller","year":"2019","unstructured":"Paller C, et al. TGF-\u03b2 receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. Prostate. 2019;79:31\u201343.","journal-title":"Prostate"},{"key":"5369_CR157","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.1073\/pnas.0602681103","volume":"103","author":"L Xu","year":"2006","unstructured":"Xu L, Begum S, Hearn JD, Hynes RO. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A. 2006;103:9023\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5369_CR158","first-page":"2315","volume":"3","author":"G Manjarrez","year":"2014","unstructured":"Manjarrez G, Herrera-M\u00e1rquez R, Neri-G\u00f3mez T, Rodr\u00edguez J. Serotonin levels in plasma and platelets of adolescents with type 1 diabetes. Glob Adv Res J Med Med Sci. 2014;3:2315\u20135159.","journal-title":"Glob Adv Res J Med Med Sci"},{"key":"5369_CR159","doi-asserted-by":"publisher","first-page":"29621","DOI":"10.1074\/jbc.M113.474163","volume":"288","author":"AA Abaeva","year":"2013","unstructured":"Abaeva AA, et al. Procoagulant platelets form an \u03b1-granule protein-covered \u201cCap\u201d on their surface that promotes their attachment to aggregates. J Biol Chem. 2013;288:29621\u201332.","journal-title":"J Biol Chem"},{"key":"5369_CR160","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4419-7913-1_9","volume-title":"Adhesion-GPCRs: Structure to Function","author":"G Aust","year":"2010","unstructured":"Aust G. Adhesion-GPCRs in Tumorigenesis. In: Yona S, Stacey M, editors. Adhesion-GPCRs: Structure to Function. Boston: Springer; 2010. p. 109\u201320. https:\/\/doi.org\/10.1007\/978-1-4419-7913-1_9."},{"key":"5369_CR161","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-4419-7913-1_7","volume-title":"Adhesion-GPCRs: Structure to Function","author":"N Strokes","year":"2010","unstructured":"Strokes N, Piao X. Adhesion-GPCRs in the CNS. In: Yona S, Stacey M, editors. Adhesion-GPCRs: Structure to Function. Boston: Springer; 2010. p. 87\u201397. https:\/\/doi.org\/10.1007\/978-1-4419-7913-1_7."},{"key":"5369_CR162","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1091\/mbc.e03-12-0886","volume":"15","author":"KD Little","year":"2004","unstructured":"Little KD, Hemler ME, Stipp CS. Dynamic regulation of a GPCR-Tetraspanin-G Protein Complex on Intact Cells: Central Role of CD81 in Facilitating GPR56-G\u03b1q\/11 Association. Mol Biol Cell. 2004;15:2375\u201387.","journal-title":"Mol Biol Cell"},{"key":"5369_CR163","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jid.2016.10.031","volume":"137","author":"N-Y Chiang","year":"2017","unstructured":"Chiang N-Y, et al. GPR56\/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated G\u03b112\/13\/RhoA signaling. J Invest Dermatol. 2017;137:727\u201336.","journal-title":"J Invest Dermatol"},{"key":"5369_CR164","first-page":"1885","volume":"40","author":"B Ji","year":"2018","unstructured":"Ji B, et al. GPR56 promotes proliferation of colorectal cancer cells and enhances metastasis via epithelial-mesenchymal transition through PI3K\/AKT signaling activation. Oncol Rep. 2018;40:1885\u201396.","journal-title":"Oncol Rep"},{"key":"5369_CR165","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1007\/s00018-015-1909-z","volume":"72","author":"K Kanchan","year":"2015","unstructured":"Kanchan K, Fuxreiter M, F\u00e9s\u00fcs L. Physiological, pathological, and structural implications of non-enzymatic protein\u2013protein interactions of the multifunctional human transglutaminase 2. Cell Mol Life Sci. 2015;72:3009\u201335.","journal-title":"Cell Mol Life Sci"},{"key":"5369_CR166","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.3390\/ijms25052797","volume":"25","author":"E Zaltron","year":"2024","unstructured":"Zaltron E, et al. The role of transglutaminase 2 in cancer: an update. Int J Mol Sci. 2024;25:2797.","journal-title":"Int J Mol Sci"},{"key":"5369_CR167","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1593\/neo.121878","volume":"15","author":"B Yakubov","year":"2013","unstructured":"Yakubov B, et al. Extracellular tissue transglutaminase activates noncanonical NF-\u03baB signaling and promotes metastasis in ovarian cancer. Neoplasia N Y N. 2013;15:609\u201319.","journal-title":"Neoplasia N Y N"},{"key":"5369_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41389-020-0204-5","volume":"9","author":"A Shinde","year":"2020","unstructured":"Shinde A, et al. Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. Oncogenesis. 2020;9:1\u201312.","journal-title":"Oncogenesis"},{"key":"5369_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05818-9","volume":"14","author":"AG Atobatele","year":"2023","unstructured":"Atobatele AG, et al. Canonical and truncated transglutaminase-2 regulate mucin-1 expression and androgen independency in prostate cancer cell lines. Cell Death Dis. 2023;14:1\u201313.","journal-title":"Cell Death Dis"},{"key":"5369_CR170","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298864","volume":"19","author":"L Huang","year":"2024","unstructured":"Huang L, et al. The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease. PLoS ONE. 2024;19:e0298864.","journal-title":"PLoS ONE"},{"key":"5369_CR171","first-page":"210","volume":"10","author":"I Wang","year":"2022","unstructured":"Wang I, et al. Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy. Am J Clin Exp Urol. 2022;10:210\u201333.","journal-title":"Am J Clin Exp Urol"},{"key":"5369_CR172","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-17-0807","volume":"23","author":"C Calagua","year":"2017","unstructured":"Calagua C, et al. Expression of PD-L1 in hormone-na\u00efve and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res. 2017;23:6812\u201322.","journal-title":"Clin Cancer Res"},{"key":"5369_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008641","volume":"16","author":"J Yuan","year":"2020","unstructured":"Yuan J, et al. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genet. 2020;16:e1008641.","journal-title":"PLoS Genet"},{"key":"5369_CR174","doi-asserted-by":"publisher","first-page":"19296","DOI":"10.1038\/s41598-020-76351-4","volume":"10","author":"AB Zaslavsky","year":"2020","unstructured":"Zaslavsky AB, et al. Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors. Sci Rep. 2020;10:19296.","journal-title":"Sci Rep"},{"key":"5369_CR175","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","volume":"12","author":"C Hinterleitner","year":"2021","unstructured":"Hinterleitner C, et al. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021;12:7005.","journal-title":"Nat Commun"},{"key":"5369_CR176","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12964-025-02034-0","volume":"23","author":"J Li","year":"2025","unstructured":"Li J, et al. PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer. Cell Commun Signal. 2025;23:29.","journal-title":"Cell Commun Signal"},{"key":"5369_CR177","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41391-020-0213-7","volume":"23","author":"O Sartor","year":"2020","unstructured":"Sartor O, et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020;23:517\u201326.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5369_CR178","doi-asserted-by":"publisher","first-page":"eaau5898","DOI":"10.1126\/scitranslmed.aau5898","volume":"11","author":"A-L Papa","year":"2019","unstructured":"Papa A-L, et al. Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models. Sci Transl Med. 2019;11:eaau5898.","journal-title":"Sci. Transl. Med."}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05369-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:03:49Z","timestamp":1788224629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05369-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":178,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5369"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05369-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board (IRB) at\u00a0The George Washington University\u00a0(IRB# NCR234939). Written informed consent was obtained from all participants prior to enrollment in the study and collection of biological specimens.","order":1,"name":"Ethics","label":"Ethics approval, consent to participate, and consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1274"}}